Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

Akifumi HagiwaraTalia C OughourlianNicholas S ChoJacob SchlossmanChencai WangJingwen YaoCatalina RaymondRichard EversonKunal PatelSergey MareninovFausto J RodriguezNoriko SalamonWhitney B PopePhioanh L NghiemphuLinda M LiauRobert M PrinsTimothy F Cloughesy Benjamin M Ellingson

Published in: Neuro-oncology (2021)

Elevated post-treatment rADC may be an early imaging biomarker for OS benefits in GBM patients receiving ICI treatment.

Keyphrases

wild type
magnetic resonance imaging
high resolution
magnetic resonance
mass spectrometry
combination therapy
low grade
computed tomography
photodynamic therapy
contrast enhanced
replacement therapy
high grade
free survival